

LEUK ACCRUAL REPORT - OPEN and recently closed STUDIES

STUDY	O R P E E G N ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	# of ACT. INSTs	# of CURR IRBs
				LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS		
S9007-Cytogen. Studies in Leuk. Pts.	1 Y 1 cytogenetics sample		3314	71	17	2	1	0	338	115
			3314	71	17	2	1	0		
S9910-Leuk Central Lab/Tissue Repos	1 Y 1 Specimen submission		1265	72	16	2	1	0	294	108
			1265	72	16	2	1	0		
S0106-AML, Mylotarg/Ara-C/Daunomycin	1 N 1 ARA-C + Daunomycin + Mylotarg	684	317	0	0	0	0	0		1
	2 ARA-C + Daunomycin		320	0	0	0	0	0		
			637	0	0	0	0	0		
	2 Y 3 ARA-C Consolidation		403	5	0	0	0	0		1
			403	5	0	0	0	0		
	3 N 4 Mylotarg	342	91	0	0	0	0	0		1
	5 Observation		91	0	0	0	0	0		
			182	0	0	0	0	0		
S0333-Non-L3 ALL, Double Induction	1 N 1 DNR + VCR + Pred + PEG-L-Asp	78	79	2	0	0	0	0	27	4
			79	2	0	0	0	0		
	2 Y 2 HD ARA-C + Mitoxantrone + GCSF		57	1	0	0	0	0	27	4
			57	1	0	0	0	0		
	3 Y 3 CTX + ARA-C + 6-MP + MTX +GCSF		40	2	0	0	0	0	27	4
			40	2	0	0	0	0		

LEUK ACCRUAL REPORT - OPEN and recently closed STUDIES

STUDY	O R P E E G N ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	# of ACT. INSTs	# of CURR IRBs
				LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS		
S0333-Non-L3 ALL, Double Induction	4 Y 4 Maintenance		19	1	0	0	0	0	27	4
			19	1	0	0	0	0		
S0432-AML, Age 70+, R115777	1 N 1 R115777 600mg BID x 21d q28d	296	83	0	0	0	0	0		
	2 R115777 600mg BID x 7d q14d		90	0	0	0	0	0		
	3 R115777 300mg BID x 21d q28d		86	0	0	0	0	0		
	4 R115777 300mg BID x 7d q14d		89	0	0	0	0	0		
			348	0	0	0	0	0		
	2 Y 5 R115777 600mg BID x 21d q28d		7	0	0	0	0	0		
	6 R115777 600mg BID x 7d q14d		2	0	0	0	0	0		
	7 R115777 300mg BID x 21d q28d		7	0	0	0	0	0		
	8 R115777 300mg BID x 7d q14d		2	0	0	0	0	0		
			18	0	0	0	0	0		
S0521-APL, Low/Int Risk, Maint vs Obs	1 N 1 ATRA + ARA-C + Daunorubicin	550	105	44	15	0	0	0	86	40
			105	44	15	0	0	0		
	2 Y 2 Consolidation		92	43	21	7	0	0	86	40
			92	43	21	7	0	0		
	3 Y 3 ATRA + 6MP + MTX	440	33	23	13	8	6	2	86	40
	4 Observation		27	18	8	3	0	0		
			60	41	21	11	6	2		
	4 Y 5 Gemtuzumab Ozogamicin		1	1	0	0	0	0	86	40

LEUK ACCRUAL REPORT - OPEN and recently closed STUDIES

STUDY	O R P E E G N ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	# of ACT. INSTs	# of CURR IRBs
				LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS		
			1	1	0	0	0	0		
S0530-ALL, Rel/Refr, Clofar. + Ara-C	1 N 1 Cytarabine + Clofarabine	35	37	0	0	0	0	0		
			37	0	0	0	0	0		
	2 Y 2 Consolidation		1	0	0	0	0	0		
			1	0	0	0	0	0		
S0535-APL, High Risk, ATRA/arsenic/GO	1 T 1 ATRA + G.O. + Arsenic	77	34	25	9	1	0	0	145	52
			34	25	9	1	0	0		
	2 Y 2 Consolidation		29	21	13	5	1	1	145	52
			29	21	13	5	1	1		
	3 Y 3 ATRA + 6-MP + MTX		12	11	8	3	3	2	145	52
			12	11	8	3	3	2		
S0605-AML, del15q, Age 60+, Revlimid	1 N 1 Revlimid	45	41	8	1	1	0	0	58	22
			41	8	1	1	0	0		
	2 Y 2 Maintenance Revlimid		12	2	0	0	0	0	58	22
			12	2	0	0	0	0		
S0703-AML, age 60+, Azacitidine G.O.	1 T 1 Hydroxyurea/Azacitidine/G.O.	153	90	59	23	6	0	0	183	55

LEUK ACCRUAL REPORT - OPEN and recently closed STUDIES

STUDY	O R P E E G N ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	# of ACT. INSTs	# of CURR IRBs
				LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS		
			90	59	23	6	0	0		
S0703-AML, age 60+, Azacitidine G.O.	2 Y 2 Azacitidine/G.O.	139	25	20	9	5	1	0	183	55
			25	20	9	5	1	0		
	3 Y 3 Azacitidine	139	20	17	8	5	1	0	183	55
			20	17	8	5	1	0		
S0805-Ph+ ALL, Dasatinib/CVAD +/- BMT	1 Y 1 Induction/Consolidation	94	1	1	1	1	1	0	72	15
			1	1	1	1	1	0		
S0919-Rel AML: Pravastatin+Ida+Ara-C	1 Y 1 Pravastatin+Idarubicin+Ara-C	55	7	7	5	4	0	0	94	34
			7	7	5	4	0	0		
	2 Y 2 Pravastatin+Idarubicin+Ara-C		2	2	2	1	1	0	94	34
			2	2	2	1	1	0		
C10403-ALL <30 yrs-Ped,Chemo. Regimen	1 Y 1 Sequential Chemotherapy	300	27	21	12	5	1	0	114	48
			27	21	12	5	1	0		
C10404-CLL, Flu/Rituxan combinations	1 Y 1 Flu/Rituximab	300	2	2	0	0	0	0	94	54
	2 Flu/Rituximab/Lenalidomide		1	0	0	0	0	0		
	3 Flu/Cy/Rituximab		3	3	2	1	1	0		
			6	5	2	1	1	0		

LEUK ACCRUAL REPORT - OPEN and recently closed STUDIES

STUDY	O R P E E G N ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	# of ACT. INSTs	# of CURR IRBs
				LAST Month	LAST Month	LAST Month	LAST DAYS	LAST DAYS		
C10603-PKC 412, blinded, FLT3 AML	1 E Total Registrations		13	10	8	5	4	1	121	64
			13	10	8	5	4	1		
E1905-MDS/CMMoL/AML-TLD,Aza+/-MS-275	1 Y 1 Azacitidine	123	8	0	0	0	0	0	112	57
	2 Azacitidine + MS-275		14	2	1	0	0	0		
			22	2	1	0	0	0		
E2905-MDS, Len vs Len + Epo	1 E Total Registrations		12	9	4	3	0	0	127	80
			12	9	4	3	0	0		

LEUK Open Studies with No Registrations

Study	Registration/Phase	OPENDT
S0805 Ph+ ALL, Dasatinib/CVAD +/- BMT	2 Maintenance	01-Sep-09
	3 Allogeneic transplantation	01-Sep-09
	4 Single-Agent Dasatinib	01-Sep-09
S0910 Rel ph-, B-ALL, Epratuzumab+Cy+Clo	1 Registration	15-Aug-10

4 rows selected.

no rows selected

LEUK SEGMENT ACCRUAL REPORT - OPEN and recently closed STUDIES

STUDY	O R P E E			SEGMENT	TOTAL REGS.	
	G	N	ARM			
S0106-AML, Mylotarg/Ara-C/Daunomycin	1	N	1 ARA-C + Daunomycin + Mylotarg	01: Initial Induction Mylotarg	317	
			1 ARA-C + Daunomycin + Mylotarg	02: Re-induction	53	
			2 ARA-C + Daunomycin	01: Initial Induction Mylotarg	319	
			2 ARA-C + Daunomycin	02: Re-induction	67	
		2	Y 3 ARA-C Consolidation	01: ARA-C Consolidation	402	
			3 ARA-C Consolidation	02: ARA-C Consolidation	228	
			3 ARA-C Consolidation	03: ARA-C Consolidation	322	
		3	N 4 Mylotarg	01: Post-Consolidation Mylotarg	90	
			4 Mylotarg	02: Post-Consolidation Mylotarg	28	
			4 Mylotarg	03: Post-Consolidation Mylotarg	21	
	S0333-Non-L3 ALL, Double Induction	4	Y	4 Maintenance	01: Maintenance Course 1	19
				4 Maintenance	02: Maintenance Course 2	15
			4 Maintenance	03: Maintenance Course 3	13	
			4 Maintenance	04: Maintenance Course 4	11	
S0432-AML, Age 70+, R115777	1	N	1 R115777 600mg BID x 21d q28d	01: Tx days 1-21	83	
			1 R115777 600mg BID x 21d q28d	02: Tx days 1-21	37	
			1 R115777 600mg BID x 21d q28d	03: Tx days 1-21	23	
			1 R115777 600mg BID x 21d q28d	04: Tx days 1-21	17	
			1 R115777 600mg BID x 21d q28d	05: Tx days 1-21	6	
			1 R115777 600mg BID x 21d q28d	06: Tx days 1-21	6	
			1 R115777 600mg BID x 21d q28d	07: Tx days 1-21	1	
			2 R115777 600mg BID x 7d q14d	01: Tx days 1-7, 15-21	90	
			2 R115777 600mg BID x 7d q14d	02: Tx days 1-7, 15-21	52	
			2 R115777 600mg BID x 7d q14d	03: Tx days 1-7, 15-21	26	
			2 R115777 600mg BID x 7d q14d	04: Tx days 1-7, 15-21	18	
			2 R115777 600mg BID x 7d q14d	05: Tx days 1-7, 15-21	11	
			2 R115777 600mg BID x 7d q14d	06: Tx days 1-7, 15-21	9	
			2 R115777 600mg BID x 7d q14d	07: Tx days 1-7, 15-21	5	
			2 R115777 600mg BID x 7d q14d	08: Tx days 1-7, 15-21	4	
			2 R115777 600mg BID x 7d q14d	09: Tx days 1-7, 15-21	2	

LEUK SEGMENT ACCRUAL REPORT - OPEN and recently closed STUDIES

STUDY	O		R P		E E		SEGMENT	TOTAL REGS.
	G	N	ARM					
S0432-AML, Age 70+, R115777	1	N	2	R115777	600mg	BID x 7d q14d	10: Tx days 1-7, 15-21	2
			2	R115777	600mg	BID x 7d q14d	11: Tx days 1-7, 15-21	2
			2	R115777	600mg	BID x 7d q14d	12: Tx days 1-7, 15-21	2
			2	R115777	600mg	BID x 7d q14d	13: Tx days 1-7, 15-21	2
			2	R115777	600mg	BID x 7d q14d	14: Tx days 1-7, 15-21	1
			2	R115777	600mg	BID x 7d q14d	15: Tx days 1-7, 15-21	1
			2	R115777	600mg	BID x 7d q14d	16: Tx days 1-7, 15-21	1
			2	R115777	600mg	BID x 7d q14d	17: Tx days 1-7, 15-21	1
			2	R115777	600mg	BID x 7d q14d	18: Tx days 1-7, 15-21	1
			3	R115777	300mg	BID x 21d q28d	01: Tx days 1-21	86
			3	R115777	300mg	BID x 21d q28d	02: Tx days 1-21	46
			3	R115777	300mg	BID x 21d q28d	03: Tx days 1-21	30
			3	R115777	300mg	BID x 21d q28d	04: Tx days 1-21	21
			3	R115777	300mg	BID x 21d q28d	05: Tx days 1-21	16
			3	R115777	300mg	BID x 21d q28d	06: Tx days 1-21	10
			3	R115777	300mg	BID x 21d q28d	07: Tx days 1-21	8
			3	R115777	300mg	BID x 21d q28d	08: Tx days 1-21	6
			3	R115777	300mg	BID x 21d q28d	09: Tx days 1-21	4
			3	R115777	300mg	BID x 21d q28d	10: Tx days 1-21	3
			3	R115777	300mg	BID x 21d q28d	11: Tx days 1-21	1
			3	R115777	300mg	BID x 21d q28d	12: Tx days 1-21	1
			3	R115777	300mg	BID x 21d q28d	13: Tx days 1-21	1
			3	R115777	300mg	BID x 21d q28d	14: Tx days 1-21	1
			3	R115777	300mg	BID x 21d q28d	15: Tx days 1-21	1
			3	R115777	300mg	BID x 21d q28d	99: Tx days 1-21	1
			4	R115777	300mg	BID x 7d q14d	01: Tx days 1-7, 15-21	89
			4	R115777	300mg	BID x 7d q14d	02: Tx days 1-7, 15-21	48
			4	R115777	300mg	BID x 7d q14d	03: Tx days 1-7, 15-21	23
			4	R115777	300mg	BID x 7d q14d	04: Tx days 1-7, 15-21	20
			4	R115777	300mg	BID x 7d q14d	05: Tx days 1-7, 15-21	12
			4	R115777	300mg	BID x 7d q14d	06: Tx days 1-7, 15-21	9
			4	R115777	300mg	BID x 7d q14d	07: Tx days 1-7, 15-21	8
			4	R115777	300mg	BID x 7d q14d	08: Tx days 1-7, 15-21	7
			4	R115777	300mg	BID x 7d q14d	09: Tx days 1-7, 15-21	4
			4	R115777	300mg	BID x 7d q14d	10: Tx days 1-7, 15-21	2
			4	R115777	300mg	BID x 7d q14d	11: Tx days 1-7, 15-21	1

LEUK SEGMENT ACCRUAL REPORT - OPEN and recently closed STUDIES

STUDY	O R P E E		G N ARM	SEGMENT	TOTAL REGS.	
S0432-AML, Age 70+, R115777	1	N	4 R115777 300mg BID x 7d q14d	12: Tx days 1-7, 15-21	1	
	4		R115777 300mg BID x 7d q14d	13: Tx days 1-7, 15-21	1	
	4		R115777 300mg BID x 7d q14d	14: Tx days 1-7, 15-21	1	
	4		R115777 300mg BID x 7d q14d	15: Tx days 1-7, 15-21	1	
	4		R115777 300mg BID x 7d q14d	16: Tx days 1-7, 15-21	1	
	2	Y	5	R115777 600mg BID x 21d q28d	01: Tx days 1-21	7
			5	R115777 600mg BID x 21d q28d	02: Tx days 1-21	6
			5	R115777 600mg BID x 21d q28d	03: Tx days 1-21	3
			5	R115777 600mg BID x 21d q28d	04: Tx days 1-21	2
			6	R115777 600mg BID x 7d q14d	01: Tx days 1-7, 15-21	2
			6	R115777 600mg BID x 7d q14d	02: Tx days 1-7, 15-21	1
			6	R115777 600mg BID x 7d q14d	05: Tx days 1-7, 15-21	1
			7	R115777 300mg BID x 21d q28d	01: Tx days 1-21	7
			7	R115777 300mg BID x 21d q28d	02: Tx days 1-21	4
			7	R115777 300mg BID x 21d q28d	03: Tx days 1-21	2
			7	R115777 300mg BID x 21d q28d	04: Tx days 1-21	2
			7	R115777 300mg BID x 21d q28d	05: Tx days 1-21	2
			7	R115777 300mg BID x 21d q28d	06: Tx days 1-21	1
			7	R115777 300mg BID x 21d q28d	07: Tx days 1-21	1
	7	R115777 300mg BID x 21d q28d	08: Tx days 1-21	1		
7	R115777 300mg BID x 21d q28d	09: Tx days 1-21	1			
8		R115777 300mg BID x 7d q14d	01: Tx days 1-7, 15-21	2		
S0521-APL,Low/Int Risk, Maint vs Obs	2	Y	2 Consolidation	01: Consolidation cycle 1: arsenic	92	
			2 Consolidation	02: Consolidation cycle 2: arsenic	73	
			2 Consolidation	03: Consolidation cycle 3:ATRA/DNR	64	
			2 Consolidation	04: Consolidation cycle 4:ATRA/DNR	56	
S0530-ALL, Rel/Refr, Clofar. + Ara-C	1	N	1 Cytarabine + Clofarabine	01: Induction cycle 1	37	
			1 Cytarabine + Clofarabine	02: Induction cycle 2	2	
S0535-APL,High Risk, ATRA/arsenic/GO	2	Y	2 Consolidation	02: Consol. 1: arsenic	29	

LEUK SEGMENT ACCRUAL REPORT - OPEN and recently closed STUDIES

STUDY	O R P E E			SEGMENT	TOTAL REGS.
	G	N	ARM		
S0535-APL, High Risk, ATRA/arsenic/GO	2	Y	2 Consolidation	03: Consol. 2: arsenic	16
			2 Consolidation	04: Consol. 3: ATRA/daunomycin	12
			2 Consolidation	05: Consol. 4: ATRA/daunomycin	10
			2 Consolidation	06: Consol. 5: G.O.	9
			2 Consolidation	07: Consol. 6: G.O.	9
S0605-AML, del15q, Age 60+, Revlimid	2	Y	2 Maintenance Revlimid	02: Cycle 2: Maint. 1	12
			2 Maintenance Revlimid	03: Cycle 3: Maint. 2	3
			2 Maintenance Revlimid	04: Next cycle: Next Maint.	3
			2 Maintenance Revlimid	05: Next cycle: Next Maint.	3
			2 Maintenance Revlimid	06: Next cycle: Next Maint.	1
			2 Maintenance Revlimid	07: Next cycle: Next Maint.	1
S0703-AML, age 60+, Azacitidine G.O.	1	T	1 Hydroxyurea/Azacitidine/G.O.	01: Cycle 1: Induction	90
			1 Hydroxyurea/Azacitidine/G.O.	02: Cycle 2: Induction	55
	3	Y	3 Azacitidine	04: Maintenance 1: cycle 4	20
			3 Azacitidine	05: Maintenance 2: cycle 5	13
			3 Azacitidine	06: Maintenance 3: cycle 6	13
			3 Azacitidine	07: Maintenance 4: cycle 7	12
S0805-Ph+ ALL, Dasatinib/CVAD +/- BMT	1	Y	1 Induction/Consolidation	01: Ind/Cons 1: CVAD/Dasatinib	1
S0919-Rel AML: Pravastatin+Ida+Ara-C	2	Y	2 Pravastatin+Idarubicin+Ara-C	02: Consolidation 1	2

114 rows selected.